Core Laboratories (CLB) Non-Current Deffered Revenue (2022 - 2026)

Core Laboratories has reported Non-Current Deffered Revenue for 5 years, with the latest figure at $28.2 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Deffered Revenue fell 3.53% year-over-year to $28.2 million; the trailing twelve-month figure through Mar 2026 stood at $28.2 million (down 3.53% YoY), and the FY2025 full-year result was $29.4 million, down 5.57% from the prior year.
• Non-Current Deffered Revenue for Q1 2026 stood at $28.2 million, down from $29.4 million in the prior quarter.
• The five-year high for Non-Current Deffered Revenue was $31.8 million in Q4 2022, with the low at $28.2 million in Q1 2026.
• Historically, Non-Current Deffered Revenue has averaged $30.2 million across 5 years, with a median of $30.4 million in 2024.
• Annual changes were most pronounced in 2024 — Non-Current Deffered Revenue gained 8.44% — and 2025, when it retreated 5.57%.
• Core Laboratories' Non-Current Deffered Revenue stood at $31.8 million in 2022, then retreated by 3.99% to $30.5 million in 2023, then climbed by 1.87% to $31.1 million in 2024, then declined by 5.57% to $29.4 million in 2025, then declined by 4.14% to $28.2 million in 2026.
• The last three Non-Current Deffered Revenue figures came in at $28.2 million (Q1 2026), $29.4 million (Q4 2025), and $31.1 million (Q3 2025), per Business Quant data.